Difference between revisions of "FGF14-AS2"
(→Expression) |
|||
| (7 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
==Annotated Information== | ==Annotated Information== | ||
| + | [[File:FGF14-AS2 expression in breast cancer in TCGA cohort.jpg|right|thumb|200px|'''FGF14-AS2 expression in breast cancer in TCGA cohort.'''<ref name="ref1" />]] | ||
| + | [[File:FGF14-AS2 expression in breast cancer in validated cohort.jpg|right|thumb|200px|'''FGF14-AS2 expression in breast cancer in validated cohort.'''<ref name="ref1" />]] | ||
| + | [[File:Kaplan–Meier analysis for the overall survival of breast cancer patients with different expression of FGF14-AS2 in TCGA cohort.jpg|right|thumb|200px|'''Kaplan–Meier analysis for the overall survival of breast cancer patients with different expression of FGF14-AS2 in TCGA cohort.'''<ref name="ref1" />]] | ||
===Approved Symbol=== | ===Approved Symbol=== | ||
FGF14-AS2 (FGF14 antisense RNA 2) | FGF14-AS2 (FGF14 antisense RNA 2) | ||
| Line 5: | Line 8: | ||
13q33.1 | 13q33.1 | ||
===RefSeq ID=== | ===RefSeq ID=== | ||
| − | |||
| − | |||
NR_036487 | NR_036487 | ||
===Expression=== | ===Expression=== | ||
| − | + | Compared with adjacent non-cancerous breast tissues, FGF14-AS2 is down-regulated in breast cancer.<ref name="ref1" /> | |
| − | |||
{| class='wikitable' style="text-align:center" | {| class='wikitable' style="text-align:center" | ||
|- | |- | ||
| Line 21: | Line 21: | ||
| | 5'-AGGTTCATAGTTGCCAGAC- 3'<ref name="ref1" /> | | | 5'-AGGTTCATAGTTGCCAGAC- 3'<ref name="ref1" /> | ||
|} | |} | ||
| − | + | ===Function=== | |
| − | + | FGF14-AS2 is involved in the progress of breast cancer and it plays a tumor suppressor gene role.<ref name="ref1" /> | |
| − | |||
| − | |||
===Disease=== | ===Disease=== | ||
| − | breast cancer | + | breast cancer <ref name="ref1" /> |
==Labs working on this lncRNA== | ==Labs working on this lncRNA== | ||
* Department of Surgical Oncology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China. | * Department of Surgical Oncology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China. | ||
| − | |||
==References== | ==References== | ||
<references> | <references> | ||
| − | <ref name="ref1"> | + | <ref name="ref1">Yang, F., et al., A novel long non-coding RNA FGF14-AS2 is correlated with progression and prognosis in breast cancer. Biochem Biophys Res Commun, 2016. 470(3): p. 479-483. |
</ref>(1) | </ref>(1) | ||
</references> | </references> | ||
Latest revision as of 07:08, 15 October 2017
Contents
Annotated Information
FGF14-AS2 expression in breast cancer in TCGA cohort.[1]
FGF14-AS2 expression in breast cancer in validated cohort.[1]
Kaplan–Meier analysis for the overall survival of breast cancer patients with different expression of FGF14-AS2 in TCGA cohort.[1]
Approved Symbol
FGF14-AS2 (FGF14 antisense RNA 2)
Chromosome
13q33.1
RefSeq ID
NR_036487
Expression
Compared with adjacent non-cancerous breast tissues, FGF14-AS2 is down-regulated in breast cancer.[1]
| Experiment | Forward primer | Reverse primer |
|---|---|---|
| qRT-PCR | 5'-AGTTCCAGTTACCATCTTCA- 3' | 5'-AGGTTCATAGTTGCCAGAC- 3'[1] |
Function
FGF14-AS2 is involved in the progress of breast cancer and it plays a tumor suppressor gene role.[1]
Disease
breast cancer [1]
Labs working on this lncRNA
- Department of Surgical Oncology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
